News

If the merger deal was successful, Salix would have been combined with, and become a wholly-owned subsidiary of, Cosmo Technologies, a subsidiary of Cosmo. As part of the

18-MC is an alpha-3-beta-4 nicotinic receptor antagonist that modulates excessive dopamine fluctuations in the mesolimbic system of the brain and this mechanism of action differs from all existing

These requests were made by treating physicians. Emergency Investigational New Drug Applications (EIND) were granted by the U.S. Food and Drug Administration (FDA). "Chimerix is committed to working

The agreement represents an innovative approach to research by focusing numerous clinical trials using multiple agents, in mono and combination regimens, on a specific disease target, in this

The company expects to release final results of the study in the fourth quarter of 2014 upon completion of statistical analysis. Preliminary interim data from this study were

The company ran this Phase 2 study using two distinct repetitive allergen challenge models: a modified Conjunctival Allergen Provocation Test (CAPT) model; and a modified Environmental Exposure Chamber

The combination therapies will be evaluated in two Phase I/II trials by Novartis in patients with non-small cell lung cancer (NSCLC). Novartis’ three molecularly targeted oncology therapies include

The recommended dosage of EYLEA in patients with macular edema following RVO is 2mg every four weeks. Regeneron chief scientific officer George Yancopoulos said RVO is a significant

NER1006 is a low volume polyethylene glycol based bowel preparation developed to provide whole bowel cleansing, with an additional focus on the ascending colon. The multicenter, randomized, parallel-group